Saturday 17 October 2026
Export ZTEKF’s income statement to Excel — free account
Zentek Ltd.
ZTEKF Healthcare Medical Instruments & Supplies
Zentek Ltd.’s revenue for fiscal 2026 (year ended March 2026) was $120,200.00, down 80.8% from fiscal 2025. In the quarter to June 2026, revenue fell 95.4%, EPS was flat, free cash flow fell 254.6% and total debt rose 6.53%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
0.39
0.04
−9.30%
Follow ZTEKF
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
— | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
— | 467.03 | 117.45 | 122.58 | |
P/FCF ratio |
— | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
— | (100.21) | (57.73) | (91.52) | |
P/B ratio |
— | 7.91 | 8.99 | 9.51 | |
Price to Tangible BV |
— | 7.91 | 8.99 | 9.51 | |
EV/Sales |
— | 471.81 | 117.73 | 123.37 | |
EV/EBITDA |
— | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
— | (15.46) | (19.68) | (20.99) | |
EV/FCF |
— | (23.04) | (28.51) | (32.36) | |
Quick Ratio |
4.49 | 0.47 | 0.67 | 0.45 | |
Current Ratio |
4.65 | 0.64 | 1.00 | 0.79 | |
Net Debt/EBITDA |
6.96 | (0.12) | 0.03 | (0.16) | |
Debt/Assets |
5.87% | 11.61% | 9.85% | 10.11% | |
Debt/Equity |
0.07 | 0.18 | 0.14 | 0.15 | |
Asset Turnover |
0.00 | 0.01 | 0.05 | 0.05 | |
Operating CF/Net income |
0.58 | 0.22 | 0.77 | 0.51 | |
Capex/Depreciation |
(4.68) | (1.19) | (1.38) | (2.31) | |
Interest Coverage |
(69.09) | (120.21) | (80.41) | (69.82) | |
Research and Development Expense of Revenue |
0.00% | 1,351.66% | 1,141.24% | 4,322.22% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 3,138.01% | 2,332.26% | 25,395.56% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 1,445.39% | 809.83% | 1,124.44% | |
Graham Net Nets |
— | (0.04) | (0.02) | (0.02) | |
Graham Number |
— | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
— | (14.02%) | (8.48%) | (7.05%) | |
Free Cash Flow Yield |
— | (4.39%) | (3.52%) | (3.11%) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.01) | (0.01) | (0.01) | (0.01) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.01) | (0.01) | (0.01) | (0.01) | |
Cash per Share |
0.10 | 0.01 | 0.01 | 0.01 | |
Shareholders Equity per Share |
0.16 | 0.07 | 0.07 | 0.08 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.16 | 0.07 | 0.07 | 0.08 | |
Free Cash Flow |
(1.27) | (0.67) | (1.50) | (1.11) | |
Working Capital |
9.98 | (0.91) | (0.01) | (0.53) | |
Capital Expenditures |
(0.42) | (0.11) | (0.13) | (0.23) | |
Net Current Asset Value |
8.67 | (2.18) | (1.24) | (1.77) | |
EV/EBIT |
— | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 4.13 | 2.68 | 50.64 | |
Price to Operating Income |
— | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
0.28 | 0.57 | 0.25 | 0.17 | |
Average Payables |
2.20 | 2.29 | 1.87 | 1.78 | |
Average Inventory |
0.46 | 0.47 | 0.62 | 0.71 | |
Average Assets |
17.83 | 12.07 | 13.03 | 13.91 | |
Average Common Equity |
14.18 | 8.85 | 10.21 | 11.05 |
Columns are period end dates